title: Use of vancomycin as a surrogate for dalbavancin in vitro susceptibility testing: results from the DISCOVER studies.
abstract: BACKGROUND
  Dalbavancin is a lipoglycopepetide antibiotic with activity against gram positive pathogens recently approved for treatment of acute bacterial skin and skin structure infections. Pending the introduction of antimicrobial susceptibility tests, we examined the utility of vancomycin inhibitory concentrations to predict dalbavancin susceptibility in a panel of isolates obtained from phase 3 registration studies.
  
  
  RESULTS
  99.6% of Staphylococcus aureus and 99.0% of beta-hemolytic streptococci which are susceptible to vancomycin will have an MIC at or below the US FDA susceptibility breakpoint for dalbavancin.
  
  
  CONCLUSIONS
  Vancomycin should be considered as a surrogate for in vitro dalbavancin susceptibility testing.
authors.affiliation: Durata Therapeutics, Inc., Branford, CT, Branford, CT, USA. mdunne@duratatx.com.
authors.forename: Michael W
authors.initials: MW
authors.lastname: Dunne
authors.affiliation: International Health Care Associates, Inc, Washington, DC, USA. dsahm@hmainc.com.
authors.forename: Dan
authors.initials: D
authors.lastname: Sahm
authors.affiliation: Durata Therapeutics, Inc., Branford, CT, Branford, CT, USA. sputtagunta@duratatx.com.
authors.forename: Sailaja
authors.initials: S
authors.lastname: Puttagunta
mesh_terms: D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000382:microbiology; D013211:Staphylococcus aureus / Q000187:drug effects*; D017334:Teicoplanin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D014640:Vancomycin / Q000008:administration & dosage*
chemical_list: D000900:Anti-Bacterial Agents; D017334:Teicoplanin; D014640:Vancomycin; C469289:dalbavancin